MedTrace Logo

Vitamin D for Preventing Recurrent Preeclampsia in Pregnant Women

NCT07288801 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2025-12-17

No results posted yet for this study

Summary

The goal of this clinical trial is to find out whether giving vitamin D to pregnant women who had pre-eclampsia in a previous pregnancy helps prevent the condition from coming back. The main question it aims to answer is:

Does vitamin D supplementation reduce the chance of pre-eclampsia recurring in pregnant women with a history of pre-eclampsia?

To answer this question, pregnant women attending the antenatal clinic at the Department of Obstetrics and Gynaecology, Nishtar Hospital Multan will be invited to join the study.

Participants will be randomly assigned to two equal groups:

* Vitamin D group: will take 4,000 IU of oral vitamin D until 36 weeks of gestation.
* Placebo group: will receive a pill identical in appearance, taste, and consistency but without vitamin D.

While on the study medication, each woman will visit the clinic every two weeks. At each visit, her blood pressure will be measured, and if it is 140/90 mmHg or higher, a urine test will check for protein to identify pre-eclampsia as per hospital protocol. Any diagnosis of pre-eclampsia will lead to standard care, and the outcome will be recorded.

At the end, researchers will compare how many women in each group developed recurrent pre-eclampsia.

This study will help answer whether vitamin D supplementation can safely reduce the risk of pre-eclampsia returning in women with a prior history - a question important for improving pregnancy outcomes and maternal health.

Conditions

Interventions

DRUG

Vitamin D

4000 IU of vitamin D will be given orally, once daily till 36-weeks of gestation

DRUG

Placebo and standard of care

Look, smell and taste alike oil emulsion drops, same number, till 36-weeks of gestation

Sponsors & Collaborators

  • Nishtar Medical University

    lead OTHER

Principal Investigators

  • Mehnaz K Professor, FCPS · Nishtar Medical University and Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-09
Primary Completion
2026-02-08
Completion
2026-02-08

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07288801 on ClinicalTrials.gov